Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/science.abc5902 http://scihub22266oqcxt.onion/10.1126/science.abc5902 32540902!7299281!32540902     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Science 2020 ; 369 (6504): 643-650 Nephropedia Template TP {{tp|p=32540902|t=2020. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability |pdf=|usr=}}{{32540902}} gab.com Text Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability JO: Science http://www.kidney.de/pget.php?&tw=1&pmid=32540902 #FOAvip The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention. Twit Text FOAVip Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability ????Science http://www.kidney.de/pget.php?&tw=1&pmid=32540902 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32540902 #FOAvip English Wikipedia <ref>{{Cite pmid|32540902}}</ref> Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability #MMPMID32540902 Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ Science 2020[Aug]; 369 (6504): 643-650 PMID32540902show ga The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention. |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal/*immunology[MESH] |Antibodies, Neutralizing/blood/*immunology[MESH] |Antibodies, Viral/blood/*immunology[MESH] |Antibody Affinity[MESH] |Antigens, Viral/immunology[MESH] |B-Lymphocyte Subsets/immunology[MESH] |Betacoronavirus/*immunology[MESH] |Broadly Neutralizing Antibodies/immunology[MESH] |COVID-19[MESH] |Cell Line, Tumor[MESH] |Coronavirus Infections/*immunology/prevention & control/therapy[MESH] |Epitopes/immunology[MESH] |Female[MESH] |Humans[MESH] |Immunologic Memory[MESH] |Immunophenotyping[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*immunology/prevention & control/therapy[MESH] |Protein Domains[MESH] |Protein Interaction Domains and Motifs/immunology[MESH] |Receptors, Coronavirus[MESH] |Receptors, Virus/metabolism[MESH] |SARS-CoV-2[MESH]Potent neutralizing antibodies from COVID-19 patients define multiple (epmc).pdf DeepDyve Pubget Overpricing